Literature DB >> 26711323

Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.

Patricia Fletcher1, Carolina Herrera1, Naomi Armanasco1, Jeremy Nuttall2, Robin J Shattock1.   

Abstract

The potential of maraviroc (MVC), a small-molecule CCR5 antagonist, as a candidate to prevent HIV-1 sexual transmission by oral or topical dosing has not yet been completely established. Using relevant cellular and mucosal tissue explant models, we show partial antiviral activity of MVC when tested in multiple preclinical dosing strategies.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26711323      PMCID： PMC4817569          DOI： 10.1089/AID.2015.0315

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  37 in total

Review 1.  Microbicides: topical prevention against HIV.

Authors:  Robin J Shattock; Zeda Rosenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

2.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

3.  HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.

Authors:  Philippe Colin; Yann Bénureau; Isabelle Staropoli; Yongjin Wang; Nuria Gonzalez; Jose Alcami; Oliver Hartley; Anne Brelot; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

4.  Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

Authors:  R Karl Malcolm; Claire J Forbes; Leslie Geer; Ronald S Veazey; Laurie Goldman; Per Johan Klasse; John P Moore
Journal:  J Antimicrob Chemother       Date:  2012-10-30       Impact factor: 5.790

5.  Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

Authors:  Claire J Forbes; Deborah Lowry; Leslie Geer; Ronald S Veazey; Robin J Shattock; Per Johan Klasse; Mark Mitchnick; Laurie Goldman; Lara A Doyle; Brendan C O Muldoon; A David Woolfson; John P Moore; R Karl Malcolm
Journal:  J Control Release       Date:  2011-08-12       Impact factor: 9.776

6.  New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.

Authors:  Javier Garcia-Perez; Patricia Rueda; Isabelle Staropoli; Esther Kellenberger; Jose Alcami; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

7.  Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

Authors:  J Gerardo García-Lerma; Wutyi Aung; Mian-er Cong; Qi Zheng; Ae S Youngpairoj; James Mitchell; Angela Holder; Amy Martin; Susan Kuklenyik; Wei Luo; Carol Yen-Chin Lin; Debra L Hanson; Ellen Kersh; Chou-Pong Pau; Adrian S Ray; James F Rooney; William A Lee; Walid Heneine
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

8.  Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

Authors:  Qiuxiang Tan; Ya Zhu; Jian Li; Zhuxi Chen; Gye Won Han; Irina Kufareva; Tingting Li; Limin Ma; Gustavo Fenalti; Jing Li; Wenru Zhang; Xin Xie; Huaiyu Yang; Hualiang Jiang; Vadim Cherezov; Hong Liu; Raymond C Stevens; Qiang Zhao; Beili Wu
Journal:  Science       Date:  2013-09-12       Impact factor: 47.728

9.  Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.

Authors:  Reem Berro; Anila Yasmeen; Ravinder Abrol; Bartosz Trzaskowski; Sarya Abi-Habib; Amy Grunbeck; Danny Lascano; William A Goddard; Per Johan Klasse; Thomas P Sakmar; John P Moore
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

10.  Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.

Authors:  Alex de Voux; Mei-Chi Chan; Asongna T Folefoc; Michael T Madziva; Colleen A Flanagan
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240
View more
  7 in total

1.  The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

Authors:  Ian McGowan; Timothy Wilkin; Raphael J Landovitz; Chunyuan Wu; Ying Chen; Mark A Marzinke; Craig W Hendrix; Paul Richardson; Susan H Eshleman; Adriana Andrade; Wairimu Chege; Peter L Anderson; Marybeth McCauley; Jason Farley; Kenneth H Mayer; Peter Anton; Rhonda M Brand; Ross D Cranston; Roy Gulick
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

2.  A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Authors:  Ian M McGowan; Sylvain Chawki; Craig W Hendrix; Peter A Anton; Mark A Marzinke; Rhonda M Brand; Jarret C Engstrom; Lisa C Rohan; Kaleab Z Abebe; Nicola Richardson-Harman; Aaron Siegel; Alex Reinhart; John Steytler; Ronald Stall; Hans Spiegel; Beatrice Chen; Sharon L Achilles; Cindy E Jacobson; Elena Khanukova; Ross D Cranston
Journal:  AIDS Res Hum Retroviruses       Date:  2021-09-14       Impact factor: 1.723

3.  The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans.

Authors:  Carolina Herrera; Mackenzie L Cottrell; John Prybylski; Angela D M Kashuba; Ronald S Veazey; Javier García-Pérez; Natalia Olejniczak; Clare F McCoy; Paul Ziprin; Nicola Richardson-Harman; José Alcami; Karl R Malcolm; Robin J Shattock
Journal:  iScience       Date:  2022-05-16

Review 4.  Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Authors:  Melanie R Nicol; Joseph A Corbino; Mackenzie L Cottrell
Journal:  J Clin Pharmacol       Date:  2018-06-14       Impact factor: 3.126

5.  HIV Trafficking Between Blood and Semen During Early Untreated HIV Infection.

Authors:  Antoine Chaillon; Davey M Smith; Christophe Vanpouille; Andrea Lisco; Parris Jordan; Gemma Caballero; Milenka Vargas; Sara Gianella; Sanjay R Mehta
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

6.  The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate.

Authors:  Carolina Herrera; Sarah Harman; Yoann Aldon; Paul Rogers; Naomi Armanasco; Paul Ziprin; Daniel Stieh; Jeremy Nuttall; Robin J Shattock
Journal:  AIDS       Date:  2021-10-01       Impact factor: 4.632

Review 7.  The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models.

Authors:  Carolina Herrera
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.